DRAGdb: Drug Resistance Associated Genes
Number of mutation entries of gyrB in ESKAPE bacteria is 39
PROVEAN score threshold is -2.5. Variants with score = or < -2.5 are considered deleterious.Variants with score > -2.5 are considered neutral.
| ORGANISM_NAME | GENE_NAME | ENSEMBL_ID | DRUG_NAME | NUCLEOTIDE_POSITION | NUCLEOTIDE_MUTATION | AMINOACID_POSITION | AMINOACID_MUTATION | PROVEAN_SCORE | SAMPLE_LOCATION |
|---|---|---|---|---|---|---|---|---|---|
| Acinetobacter baumannii | gyrB | AO727_09035 | Fluoroquinolone (Ciprofloxacin) | 1437 | GAA - GAT | 479 | Glu - Asp | -2.084 | NA |
| Acinetobacter baumannii | gyrB | AO727_09035 | Fluoroquinolone (Ciprofloxacin) | 1930 | GAT - TAT | 644 | Asp - Tyr | -1.607 | NA |
| Acinetobacter baumannii | gyrB | AO727_09035 | Fluoroquinolone (Ciprofloxacin) | 2030 | GCG - GTG | 677 | Ala - Val | -0.169 | NA |
| Staphylococcus aureus | gyrB | CH52_05425 / CH52_12295 | Non-Fluorinated Quinolones | 1429 - 1431 | NA | 477 | Glu - Val | -6.347 | NA |
| Staphylococcus aureus | gyrB | CH52_05425 / CH52_12295 | Novobiocin | 431 | AGA - ATA | 144 | Arg - Ile | -5.475 | NA |
| Staphylococcus aureus | gyrB | CH52_05425 / CH52_12295 | Novobiocin | 253 | GGT - AGT | 85 | Gly - Ser | -4.356 | NA |
| Staphylococcus aureus | gyrB | CH52_05425 / CH52_12295 | Novobiocin | 167 | ATC - AGC | 56 | Ile - Ser | -4.351 | NA |
| Staphylococcus aureus | gyrB | CH52_05425 / CH52_12295 | Quinolone | 1423 | A - G | 475 | Asn - Asp | -4.292 | NA |
| Staphylococcus aureus | gyrB | CH52_05425 / CH52_12295 | Novobiocin | 517 | ACT - GCT | 173 | Thr - Ala | -4.284 | NA |
| Staphylococcus aureus | gyrB | CH52_05425 / CH52_12295 | Novobiocin | 432 | AGA - AGT | 144 | Arg - Ser | -3.785 | NA |
| Staphylococcus aureus | gyrB | CH52_05425 / CH52_12295 | Novobiocin | 432 | AGA - AGT | 144 | Arg - Ser | -3.785 | NA |
| Staphylococcus aureus | gyrB | CH52_05425 / CH52_12295 | Novobiocin | 432 | AGA - AGT | 144 | Arg - Ser | -3.785 | NA |
| Staphylococcus aureus | gyrB | CH52_05425 / CH52_12295 | Novobiocin | 305 | ATT - AGT | 102 | Ile - Ser | -3.588 | NA |
| Staphylococcus aureus | gyrB | CH52_05425 / CH52_12295 | Novobiocin | 305 | ATT - AGT | 102 | Ile - Ser | -3.588 | NA |
| Staphylococcus aureus | gyrB | CH52_05425 / CH52_12295 | Quinolone | 1431 | A - T | 477 | Glu - Asp | -2.727 | NA |
| Staphylococcus aureus | gyrB | CH52_05425 / CH52_12295 | Novobiocin | 305 | ATT - ACT | 102 | Ile - Thr | -2.688 | NA |
| Staphylococcus aureus | gyrB | CH52_05425 / CH52_12295 | Novobiocin | 266 | GAT - GGT | 89 | Asp - Gly | -1.022 | NA |
| Staphylococcus aureus | gyrB | CH52_05425 / CH52_12295 | Novobiocin | 383 | TCA - TTA | 128 | Ser - Leu | -0.838 | NA |
| Staphylococcus aureus | gyrB | CH52_05425 / CH52_12295 | Fluoroquinolone | 1497 | T - C | 439 | Ala - Ala | 0 | Egypt |
| Staphylococcus aureus | gyrB | CH52_05425 / CH52_12295 | Fluoroquinolone | 1578 | A - G | 465 | Lys - Lys | NA | Egypt |
| Staphylococcus aureus | gyrB | CH52_05425 / CH52_12295 | Fluoroquinolone (Sparfloxacin) | 1213 - 1227 | NA | 405 - 409 | deletion | NA | NA |
| Staphylococcus aureus | gyrB | CH52_05425 / CH52_12295 | Fluoroquinolone (Ciprofloxacin) | 1579 | A - G | NA | NA | NA | NA |
| Staphylococcus aureus | gyrB | CH52_05425 / CH52_12295 | Fluoroquinolone (Ciprofloxacin) | 1579 | A - G | NA | NA | NA | NA |
| Pseudomonas aeruginosa | gyrB | DQ20_28490 | Fluoroquinolone (Norfloxacin) | 239 | TCG - TTG | 80 | Ser - Leu | NA | NA |
| Pseudomonas aeruginosa | gyrB | DQ20_28490 | Fluoroquinolone (Ciprofloxacin) | 1371 | GAA - GAG | 457 | Glu - Glu | NA | South China |
| Pseudomonas aeruginosa | gyrB | DQ20_28490 | Fluoroquinolone (Ciprofloxacin) | 1377 | GCG - GCA | 459 | Ala - Ala | NA | South China |
| Pseudomonas aeruginosa | gyrB | DQ20_28490 | Fluoroquinolone | 1391 | C - T | 464 | Ser - Phe | NA | NA |
| Pseudomonas aeruginosa | gyrB | DQ20_28490 | Fluoroquinolone (Ciprofloxacin) | 1397 | C - T | 466 | Ser - Phe | NA | NA |
| Pseudomonas aeruginosa | gyrB | DQ20_28490 | Fluoroquinolone (Ciprofloxacin) | 1400 | C - T | 467 | Ser - Phe | NA | South China |
| Pseudomonas aeruginosa | gyrB | DQ20_28490 | Fluoroquinolone (Ciprofloxacin) | 1404 | A - T | 468 | Gln - His | NA | South China |
| Pseudomonas aeruginosa | gyrB | DQ20_28490 | Fluoroquinolone (Levofloxacin) | 147 | A - T | 469 | Glu - Asp | NA | NA |
| Pseudomonas aeruginosa | gyrB | DQ20_28490 | Fluoroquinolone (Ciprofloxacin) | 1416 | ACG - ACT | 472 | Thr - Thr | NA | South China |
| Pseudomonas aeruginosa | gyrB | DQ20_28490 | Fluoroquinolone (Ciprofloxacin) | 1425 | ACC - ACT | 475 | Thr - Thr | NA | South China |
| Pseudomonas aeruginosa | gyrB | DQ20_28490 | Fluoroquinolone (Ciprofloxacin) | 1446 | GGC - GGT | 482 | Gly - Gly | NA | South China |
| Pseudomonas aeruginosa | gyrB | DQ20_28490 | Fluoroquinolone (Ciprofloxacin) | 1455 | GAA - GAG | 485 | Glu - Glu | NA | South China |
| Klebsiella pneumoniae | gyrB | Kpn2146_5456 | Fluoroquinolone (Ciprofloxacin) | 1075 | T - G | 359 | Ser - Ala | NA | Seoul in South Korea |
| Klebsiella pneumoniae | gyrB | Kpn2146_5456 | Fluoroquinolone (Ciprofloxacin) | 1099 - 1101 | NA | 367 | Ser - Thr | NA | Seoul in South Korea |
| Enterobacter cloacae | gyrB | MC57_08020 | Fluoroquinolone (Ciprofloxacin / Levofloxacin) | 1387 | T - G | 463 | Ser - Ala | NA | NA |
| Enterobacter cloacae | gyrB | MC57_08020 | Fluoroquinolone (Ciprofloxacin / Levofloxacin) | 1391 | C - T | 464 | Ser - Phe | NA | NA |